ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2019
Employing a PLGA-TPGS based nanoparticle to improve the ocular delivery of Acyclovir.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Advances in dry eye disease: from immunopathological mechanisms to emerging ophthalmic drug delivery systems.Frontiers in medicine · 2026Review
- Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.Frontiers in pharmacology · 2026Review
- Synthesis and performance optimization of multi-bioactive compound-loaded nanocarriers for antimicrobial applications.Scientific reports · 2025Article
- Selenium Nanoparticles: Synthesis, Stability and In Vitro Evaluation in Human Lens Epithelial Cells.Pharmaceutics · 2025Article
- Epilepsy Treatment and Diagnosis Enhanced by Current Nanomaterial Innovations: A Comprehensive Review.Molecular neurobiology · 2025Review
- TPGS-modified Chitosan Nanoparticles of EGFR Inhibitor: Physicochemical andCurrent drug delivery · 2025Article
- Advances in dorzolamide hydrochloride delivery: harnessing nanotechnology for enhanced ocular drug delivery in glaucoma management.Discover nano · 2024Review
- In vivo evaluation of a Nano-enabled therapeutic vitreous substitute for the precise delivery of triamcinolone to the posterior segment of the eye.Drug delivery and translational research · 2024Article
- Mechanistic Computational Modeling of Implantable, Bioresorbable Drug Release Systems.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- Polymer-Based Nanoparticles as Drug Delivery Systems for Purines of Established Importance in Medicine.Nanomaterials (Basel, Switzerland) · 2023Review
- [Preparation of an ophthalmic formulation of TPGS-modified insulin-loaded liposomes and itsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy.Pharmaceutics · 2023Article
- Topical Application of Linezolid-Loaded Chitosan Nanoparticles for the Treatment of Eye Infections.Nanomaterials (Basel, Switzerland) · 2023Article
- Mesoporous Silica Nanoparticles Coated with Carboxymethyl Chitosan for 5-Fluorouracil Ocular Delivery: Characterization, In Vitro and In Vivo Studies.Molecules (Basel, Switzerland) · 2023Article
- TPGS Decorated Liposomes as Multifunctional Nano-Delivery Systems.Pharmaceutical research · 2023Review
- Antiviral role of nanomaterials: a material scientist's perspective.RSC advances · 2022Review
- Development of a naringenin microemulsion as a prospective ophthalmic delivery system for the treatment of corneal neovascularization:Drug delivery · 2022Article
- An Oral 3D Printed PLGA-Tocopherol PEG Succinate Nanocomposite Hydrogel for High-Dose Methotrexate Delivery in Maintenance Chemotherapy.Biomedicines · 2022Article
- Effect of Solvents, Stabilizers and the Concentration of Stabilizers on the Physical Properties of Poly(d,l-lactide-Pharmaceutics · 2022Article
- Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Delivering drugs via the ocular route has always been a challenge for poorly soluble drugs. The various anatomical and physiological barriers in the eye cavity hinder the residence of drugs within the corneal and precorneal regions. In this study, the nanosystem that could sufficiently deliver the poorly soluble Acyclovir topically via ocular route. Our nanosystem is composed of the biocompatible PLGA polymer stabilized with TPGS which possess a high emulsifying capacity and is also known as P-gp inhibitor. The optimized nanoparticles were prepared with 0.3% TPGS and had particle-size of 262.3 nm, zeta-potential of +15.14 mV. The physicochemical-characterization,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.